

Selenium for COVID-19: real-time meta-analysis of 12 studies (4 treatment studies and 8 sufficiency studies)

@CovidAnalysis, September 2026, Version 6 (V1 2023), c19early.org/semeta.html

Abstract

Meta-analysis using the most serious outcome reported shows 34% [-40-69%] lower risk, without reaching statistical significance. Results are similar for Randomized Controlled Trials and slightly worse for higher quality studies.

One study shows significant benefit.

8 sufficiency studies analyze outcomes based on serum levels, showing 58% [38-71%] lower risk for patients with higher selenium levels.

1 RCT with 100 patients has not reported results (4 years late)¹.


The European Food Safety Authority has found evidence for a causal relationship between the intake of selenium and optimal immune system function^{2,3}. Sufficiency studies show COVID-19 associated with low selenium levels, however there is very limited and conflicting results for clinical outcomes with selenium treatment.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. Selenium currently has no early treatment studies. Dietary sources may be preferred. The quality of non-prescription supplements varies widely⁴⁻⁶. All data and sources to reproduce this analysis are in the appendix.

Fan et al. present another meta-analysis for selenium, showing significant improvement for cases.

Evolution of COVID-19 clinical evidence


Meta-analysis results over time



Serious Outcome Risk



Selenium for COVID-19



SELENIUM FOR COVID-19 — HIGHLIGHTS

Meta-analysis of studies to date shows no significant improvements with selenium.

Real-time updates and corrections with a consistent protocol for 226 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.

Introduction

Immediate treatment recommended




Fig. 1. SARS-CoV-2 spike protein fibrin binding leads to thromboinflammation and neuropathology, from⁸.

SARS-CoV-2 infection primarily begins in the upper respiratory tract and may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems, which may lead to cytokine storm, pneumonia, ARDS, neurological injury⁹⁻²⁵ and cognitive deficits^{12,17}, cardiovascular complications²⁶⁻³², DNA damage³³⁻³⁶, organ failure, and death. Even mild untreated infections may result in persistent cognitive deficits³⁷—the spike protein binds to fibrin leading to fibrinolysis-resistant blood clots, thromboinflammation, and neuropathology. Minimizing replication as early as possible is recommended.

Many treatments are expected to modulate infection

SARS-CoV-2 infection and replication involves the complex interplay of 500+ host and viral proteins and other factors^{A,38-45}, providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 12,000 compounds may reduce COVID-19 risk⁴⁶, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.

Supporting research

Selenium has been identified by the European Food Safety Authority (EFSA) as having sufficient evidence for a causal relationship between intake and optimal immune system function^{2,3,47}. Selenium may be beneficial for COVID-19 by inhibiting ferroptosis, an oxidative stress-induced cell death pathway implicated in COVID-19 pathogenesis⁴⁸. Selenium enhances immune response, inhibits ROS production, and protects against ferroptosis via GPX4 induction⁴⁹.

Analysis

We analyze all significant controlled studies of selenium for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random-effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, Randomized Controlled Trials (RCTs), and higher quality studies.

	Relative Risk	Studies	Patients
All studies	0.66 [0.31-1.40]	4	20K
After exclusions	0.78 [0.30-2.06]	2	6,103
RCTs	0.65 [0.11-3.73]	1	122
Hospitalization	0.78 [0.30-2.06]	2	6,103
Cases	0.59 [0.18-1.98]	2	10K

Table 1. Random-effects meta-analysis for all stages combined, for Randomized Controlled Trials, after exclusions, and for specific outcomes. Results show the relative risk with treatment and the 95% confidence interval.

	Late treatment	Prophylaxis
All studies	0.65 [0.11-3.73]	0.64 [0.26-1.59]
After exclusions		0.78 [0.30-2.06]
RCTs	0.65 [0.11-3.73]	
Hospitalization		0.78 [0.30-2.06]
Cases		0.59 [0.18-1.98]

Table 2. Random-effects meta-analysis results by treatment stage. Results show the relative risk with treatment and the 95% confidence interval.

Treatment timing

Fig. 2 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early treatment refers to treatment immediately or soon after symptoms appear, while late treatment refers to more delayed treatment.

Preclinical Research

Selenium may be beneficial for COVID-19 by inhibiting ferroptosis, an oxidative stress-induced cell

death pathway implicated in COVID-19 pathogenesis⁴⁸.

2 *in vitro* studies support the efficacy of selenium^{50,51}.

An *in vivo* animal study supports the efficacy of selenium⁵².

Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.

Results

Table 1 summarizes the results for all stages combined, for Randomized Controlled Trials, after exclusions, and for specific outcomes. Table 2 shows results by treatment stage. Fig. 3 shows a timeline of the results in selenium studies. Fig. 4 plots individual results by treatment stage. Fig. 5, 6, 7, 8, and 9 show forest plots for random-effects meta-analysis of all studies with pooled effects, mortality results, hospitalization, cases, and sufficiency studies.

Timeline of COVID-19 selenium studies (pooled effects)



Fig. 3. Timeline of results in selenium studies.




Fig. 2. Treatment stages.

Efficacy in COVID-19 selenium studies (pooled effects)

c19early.org
September 2026




Fig. 4. Scatter plot showing the most serious outcome in all studies, and for studies within each stage. Diamonds shows the results of random-effects meta-analysis.

4 selenium COVID-19 studies

c19early.org
September 2026



Fig. 5. Random-effects meta-analysis for all studies. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

1 selenium COVID-19 mortality result

c19early.org
September 2026




Fig. 6. Random-effects meta-analysis for mortality results.

2 selenium COVID-19 hospitalization results




Fig. 7. Random-effects meta-analysis for hospitalization.

2 selenium COVID-19 case results




Fig. 8. Random-effects meta-analysis for cases.

8 selenium COVID-19 sufficiency studies




Fig. 9. Random-effects meta-analysis for sufficiency studies. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below.

Randomized Controlled Trials (RCTs)

Fig. 10 shows a forest plot for random-effects meta-analysis of all Randomized Controlled Trials. RCT results are included in Table 1 and Table 2. Currently there is only one RCT.

RCTs have many potential biases

RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases⁵³, and analysis of double-blind RCTs has identified extreme levels of bias⁵⁴. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world us-

age or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases; errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, reporting, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.

Conflicts of interest for COVID-19 RCTs

RCTs are expensive and many RCTs are funded by pharmaceutical companies or other organizations with conflicts of interest, for example governments that previously denied treatment with the study drug. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example *Als-Nielsen et al.* analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. *Bekelman et al.* and *Lundh et al.* show that industry-sponsored studies are more likely to be favorable. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.

RCTs for novel acute diseases requiring rapid treatment

High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 226 treatments we have analyzed, 67% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments. They may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration.

RCT bias for widely available treatments

RCTs have a bias against finding an effect for interventions that are widely available—patients that believe they need the intervention are more likely to decline participation and take the intervention. RCTs for selenium are more likely to enroll low-risk participants that do not need treatment to recover, making the results less applicable to clinical practice. This bias is likely to be greater for widely known treatments, and may be greater when the risk of a serious outcome is overstated. This bias does not apply to the typical pharmaceutical trial of a new drug that is otherwise unavailable.

Observational studies have been shown to be reliable

Evidence shows that observational studies can also provide reliable results. *Concato et al.* found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. *Anglemyer et al.* analyzed reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates.

We performed a similar analysis across the 226 treatments we cover, showing no significant difference in the results of RCTs compared to observational studies, RR 0.97 [0.91-1.03]⁶¹. Similar results are found for all low-cost treatments, RR 0.98 [0.90-1.06]. High-cost treatments show a non-significant trend towards

COVID-19 RCT vs. observational results from 6,000+ studies




Fig. 11. For COVID-19, observational study results do not systematically differ from RCTs, RR 0.97 [0.91-1.03] across 226 treatments⁵⁸.

RCTs showing greater efficacy, RR 0.92 [0.84-1.02]. Details can be found in the supplementary data.

Lee et al. showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or remote survey bias may have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see^{63,64}.

RCTs may be less reliable

Concato et al. report a paradoxical finding—RCT results had higher variability, and only RCTs were found to sometimes report significant results the opposite of the overall result. The same trend is seen for the most popular (most politicized) COVID-19 treatments—considering all statistically significant results reported in studies, RCTs are slightly more likely to report a result in the opposite direction. In other words, for these COVID-19 treatments and for the topics covered by *Concato et al.*, assuming causality from a single study is more likely to result in an incorrect conclusion for RCTs.

Increased risk of inconsistent results for RCTs suggests higher prevalence of bias, which may arise due to many issues including design bias, conflicts of interest, treatment differences by physicians aware of allocation, attrition bias, ascertainment bias, randomization failures, errors, or fraud.

Using all studies identifies efficacy 8+ months faster (9+ months for low-cost treatments)

Currently, 59 of the treatments we analyze show statistically significant efficacy or harm, defined as $\geq 10\%$ decreased risk or $>0\%$ increased risk from ≥ 3 studies. Of these, 54% have been confirmed in RCTs, with a mean delay of 7.8 months (62% with 8.7 months delay for low-cost treatments). The remaining treatments either have no RCTs, or the point estimate is consistent.

All studies must be carefully analyzed

Neither observational studies nor RCTs prove causation—any study can be flawed or fraudulent. We need much more, for example a combination of results from many independent teams, detailed understanding of each study, knowledge of conflicts/team reliability, dose-response relationships, delay-response relationships, logical results across outcomes, or details consistent with pre-clinical expectations.

All studies must be evaluated individually. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta-analyses.

1 selenium COVID-19 Randomized Controlled Trial

c19early.org
September 2026




Fig. 10. Random-effects meta-analysis for all Randomized Controlled Trials. This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

Unreported RCTs

1 selenium RCT has not reported results¹. The trial reports report an estimated total of 100 patients. The result is delayed over 4 years.

Exclusions

To avoid bias in the selection of studies, we analyze all non-retracted studies. Here we show the results after excluding studies with major issues likely to alter results, non-standard studies, and studies where very minimal detail is currently available. Our bias evaluation is based on analysis of each study and identifying when there is a significant chance that limitations will substantially change the outcome of the study. We believe this can be more valuable than checklist-based approaches such as Cochrane GRADE, which can be easily influenced by potential bias, may ignore or underemphasize serious issues not captured in the checklists, and may overemphasize issues unlikely to alter outcomes in specific cases (for example certain specifics of randomization with a very large effect size and well-matched baseline characteristics).

The studies excluded are as below. Fig. 12 shows a forest plot for random-effects meta-analysis of all studies after exclusions.

Hafizi, data issues pending author response.

Holt, significant unadjusted confounding possible.

2 selenium COVID-19 studies after exclusions




Fig. 12. Random-effects meta-analysis for all studies after exclusions. This plot shows pooled effects, see the specific outcome analyses for individual outcomes.

Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

Media Censorship


Low-cost treatments were subject to bias and censorship during the pandemic. Scientific bias is seen in the design, analysis, presentation, and selective reporting of studies, which often favored negative results. A similar bias is seen in the media coverage for low-cost treatments. While broadly seen, bias was particularly notable for ivermectin and hydroxychloroquine, e.g., Scott Alexander noted that "if you say anything in favor of ivermectin you will be cast out of civilization and thrown into the circle of social hell reserved for Klan members and 1/6 insurrectionists. All the health officials in the world will shout 'horse dewormer!' at you and compare you to Josef Mengele."⁶⁷

We analyze media coverage for the 226 treatments we cover using Altmetric⁶⁸, which reports the number of ~12,000 tracked news outlets that covered each study⁶⁹. Studies are considered to have received significant media coverage if they were covered by at least 0.5% of the tracked news outlets. Fig. 13, 14, and 15 show the bias toward negative results for low-cost treatments, in contrast to the opposite bias for high-profit treatments. This may result in widespread incorrect perceptions on the relative efficacy of high-profit and low-cost treatments. The impact is significant—increased cost limits the use of high-profit treatments and treatment equity, and high-profit treatments were also more difficult to access, especially for earlier treatment which improves efficacy and minimizes community transmission.

Media coverage was highly biased High-profit: preferred positive results Low-cost: preferred negative results

Media preferred to cover positive results for high-profit treatments. And negative/inconclusive results for low-cost treatments.

Randomized trials only



Many studies show lower risk with low-cost treatments 98% of these were not covered by the media

Coverage of positive vs. negative/inconclusive results; whiskers are 95% confidence intervals. Data from Altmetric. Log scale. See: c19early.org/msm.html


Fig. 13. Media was more likely to cover negative or inconclusive results for low-cost treatments, and positive results for high-profit treatments.

Media censorship for COVID-19 low-cost treatments

Media selectively covered negative studies for low-cost treatments


Only 18 positive studies were covered:

fluvoxamine (3), HCQ (2), antiandrogens (2), budesonide (2), vitamin D, melatonin, probiotics, ivermectin, cannabidiol, famotidine, curcumin, resveratrol, UDCA



53 negative studies were covered:

HCQ (15), ivermectin (7), lopinavir/r (5), vitamin D (5), azithromycin (4), zinc (2), vitamin C (2), metformin (2), fluvoxamine (2), indomethacin, colchicine, selenium, probiotics, vitamin A, ibuprofen, antiandrogens, vitamin B9, cannabidiol



Data from Altmetric: studies receiving significant mainstream media coverage from 6,000+ studies for 226 treatments

Fig. 14. Mainstream media was biased against positive results for low-cost treatments.

Media coverage for COVID-19 high-profit treatments

Media selectively covered positive studies for high-profit treatments

28 positive studies were covered:

tocilizumab (5), paxlovid (5), conv. plasma (4), casirivimab/conv. plasma (3), molnupiravir (3), remdesivir (2), peg. lambda (2), sargramostim (2), sarilumab, tixagevimab/c.



11 negative studies were covered:

remdesivir (4), conv. plasma (2), molnupiravir, bebtelovimab, sotrovimab, bamlan./e., paxlovid



97% of negative studies were not covered:



Data from Altmetric: studies receiving significant mainstream media coverage from 6,000+ studies for 226 treatments

Fig. 15. In contrast to the results for low-cost treatments, mainstream media was biased towards positive results for high-cost treatments.

A combination of factors may have led to the media's suppression of low-cost treatments:

- Politicization led to a media environment where coverage was often framed to support a political narrative rather than to provide objective scientific information. As Scott Alexander said: "if you say anything in favor of ivermectin you will be cast out of civilization and thrown into the circle of social hell reserved for Klan members and 1/6 insurrectionists. All the health officials in the world will shout 'horse dewormer!' at you and compare you to Josef Mengele." There was strong social pressure to discredit low-cost treatments.
- Censorship of information conflicting with selected authorities. For example, individuals and organizations presenting conflicting science were often banned on Twitter and YouTube.
- FDA requires "no adequate, approved, and available alternatives" in order to grant an EUA for novel high-profit interventions, creating a strong incentive for authorities to ignore or downplay existing low-cost treatments.
- Regulatory capture biases authorities towards high-profit interventions.
- Authorities ignored most evidence for low-cost treatments, for example the NIH references only 2% of studies in delayed, rarely-updated, biased commentaries with no quantitative analysis.
- Media coverage of science is often not very accurate, e.g., misunderstanding confounding issues. For example the media widely considered the RECOVERY HCQ RCT to be conclusive on efficacy, but very late treatment of late stage patients (mostly on oxygen already) with an excessive toxic dose (shown dangerous in a dose comparison RCT) provides no information on the recommended early/prophylactic treatment. With difficulting in understanding basic confounders like treatment delay and dose, the media may favor deferring to authorities. Many studies for low-cost treatments require greater expertise to analyze. Relatively few journalists have a strong ability to analyze clinical trials and are outnumbered by the rest.
- Substantial funding from pharmaceutical advertising biases editorial decisions towards high-profit interventions.
- PR power - companies/teams with strong PR presence are favored in the media, which correlates with high-profit and high conflict of interest studies.
- The media was very negative in general, inflating risk, fear, and anxieties. A negative bias may improve ratings and revenue, increasing motivation to continue watching coverage. A combination of low-cost treatments greatly reducing risk conflicts with the negative narrative.

Heterogeneity

Heterogeneity in COVID-19 studies arises from many factors including:

Treatment delay

The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours^{70,71}. Baloxavir marboxil studies for influenza also show that treatment delay is critical — *Ikematsu et al.* report an 86% reduction in cases for post-exposure prophylaxis, *Hayden et al.* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and *Kumar et al.* report only 2.5 hours improvement for inpatient treatment.

Treatment delay	Result
Post-exposure prophylaxis	86% fewer cases ⁷²
<24 hours	-33 hours symptoms ⁷³
24-48 hours	-13 hours symptoms ⁷³
Inpatients	-2.5 hours to improvement ⁷⁴

Table 3. Studies of baloxavir marboxil for influenza show that early treatment is more effective.

Fig. 16 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 226 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.




Fig. 16. Early treatment is more effective. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 226 treatments.

Patient demographics

Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in *López-Medina et al.*

SARS-CoV-2 variants

Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants⁷⁶, for example the Gamma variant shows significantly different characteristics⁷⁷⁻⁸⁰. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants^{81,82}.

Treatment regimen

Effectiveness may depend strongly on the dosage and treatment regimen.

Medication quality

The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. *Williams et al.* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. *Xu et al.* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer. Non-prescription supplements may show very wide variations in quality^{4,5}.

Other treatments

The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic⁸⁵⁻¹⁰⁹, therefore efficacy may depend strongly on combined treatments.

Effect measured

Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.

Meta-analysis

The distribution of studies will alter the outcome of a meta-analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta-analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta-analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

Pooled Effects

Combining studies is required

For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results.

"The studies reported different outcomes" is not a good reason for disregarding results. Pooling the results of studies reporting different outcomes allows us to use more of the available information. Logically we should, and do, use additional information when evaluating treatments—for example dose-response and treatment delay-response relationships provide additional evidence of efficacy that is considered when reviewing the evidence for a treatment.

Specific outcome and pooled analyses

We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.

Ethical and practical issues limit high-risk trials

Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster and safer collection of evidence.

Validating pooled outcome analysis for COVID-19

For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.

Analysis of the the association between different outcomes across studies from all 226 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Fig. 17 shows that lower hospitalization is very strongly associated with lower mortality ($p < 0.0000000001$). Similarly, Fig. 18 shows that improved recovery is very strongly associated with lower mortality ($p < 0.0000000001$). Considering the extremes, *Singh et al.* show an association between viral clearance and hospitalization or death, with $p = 0.003$ after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Fig. 19 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to *Singh et al.*, with higher confidence due to the larger number of studies. As with *Singh et al.*, the confidence increases when excluding the outlier treatment, from $p = 0.0000000074$ to $p = 0.00000000015$.




Fig. 17. Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.




Fig. 18. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.




Fig. 17. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.

Pooled outcomes identify efficacy 5 months faster (7 months for RCTs)

Currently, 59 of the treatments we analyze show statistically significant efficacy or harm, defined as $\geq 10\%$ decreased risk or $>0\%$ increased risk from ≥ 3 studies. 85% of these have been confirmed with one or more specific outcomes, with a mean delay of 4.6 months. When restricting to RCTs only, 53% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 7.5 months. Fig. 20 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.




Fig. 20. The time when studies showed that treatments were effective, defined as statistically significant improvement of $\geq 10\%$ from ≥ 3 studies. Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

Limitations

Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as differences in treatment delay are more likely to hide efficacy.

Summary

Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta-analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.

Discussion

Publication bias

Publishing is often biased towards positive results, however evidence suggests that there may be a negative bias for inexpensive treatments for COVID-19. Both negative and positive results are very important for COVID-19, media in many countries prioritizes negative results for inexpensive treatments (inverting the typical incentive for scientists that value media recognition), and there are many reports of difficulty publishing positive results¹¹¹⁻¹¹⁴. For selenium, there is currently not enough data to evaluate publication bias with high confidence.

One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide more opportunities for the specifics of data extraction and adjustments to influence results.

Fig. 21 shows a scatter plot of results for prospective and retrospective treatment studies. The median effect size for retrospective studies is 13% improvement, compared to 57% for prospective studies, suggesting a potential bias towards publishing results showing lower efficacy.




Fig. 21. Prospective vs. retrospective studies. The diamonds show the results of random-effects meta-analysis.

Conflicts of interest

Pharmaceutical drug trials often have conflicts of interest whereby sponsors or trial staff have a financial interest in the outcome being positive. Selenium for COVID-19 lacks this because it is an inexpensive and widely available supplement. In contrast, most COVID-19 selenium trials have been run by physicians on the front lines with the primary goal of finding the best methods to save human lives and minimize the collateral damage caused by COVID-19. While pharmaceutical companies are careful to run trials under optimal conditions (for example, restricting patients to those most likely to benefit, only including patients that can be treated soon after onset when necessary, and ensuring accurate dosing), not all selenium trials represent the optimal conditions for efficacy.

Limitations

Summary statistics from meta-analysis necessarily lose information. As with all meta-analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.

Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone⁸⁵⁻¹⁰⁹. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

Notes

1 of 4 studies combine treatments. The results of selenium alone may differ. 1 of 1 RCTs use combined treatment. Currently all studies are peer-reviewed. *Fan et al.* present another meta-analysis for selenium, showing significant improvement for cases.

Reviews

Many reviews cover selenium for COVID-19, presenting additional background on mechanisms and related results, including^{48,49,115-126}.

Other studies

Additional preclinical or review papers suggesting potential benefits of selenium for COVID-19 include¹²⁹⁻¹³⁵. We have not reviewed these studies in detail.

Perspective

Results compared with other treatments

SARS-CoV-2 infection and replication involves a complex interplay of 500+ host and viral proteins and other factors³⁸⁻⁴⁵, providing many therapeutic targets. Over 12,000 compounds have been predicted to reduce COVID-19 risk⁴⁶, either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Fig. 22 shows an overview of the results for selenium in the context of multiple COVID-19 treatments, and Fig. 23 shows a plot of efficacy vs. cost for COVID-19 treatments.

Efficacy in COVID-19 studies (pooled effects)

c19early.org
September 2026




Fig. 22. Scatter plot showing results within the context of multiple COVID-19 treatments. Diamonds shows the results of random-effects meta-analysis. 0.5% of 12,000+ proposed treatments show efficacy¹³⁶.

Efficacy vs. cost for COVID-19 treatments

c19early.org
September 2026




Fig. 23. Efficacy vs. cost for COVID-19 treatments.

Conclusion

Meta-analysis using the most serious outcome reported shows 34% [-40-69%] lower risk, without reaching statistical significance. Results are similar for Randomized Controlled Trials and slightly worse for higher quality studies. One study shows significant benefit. 8 sufficiency studies analyze outcomes based on serum levels, showing 58% [38-71%] lower risk for patients with higher selenium levels.

The European Food Safety Authority has found evidence for a causal relationship between the intake of selenium and optimal immune system function^{2,3}. Sufficiency studies show COVID-19 associated with low selenium levels, however there is very limited and conflicting results for clinical outcomes with selenium treatment.

Fan et al. present another meta-analysis for selenium, showing significant improvement for cases.

Contact. Contact us on X at @CovidAnalysis.

Funding. We have received no funding or compensation in any form, and do not accept donations. This is entirely volunteer work.

Conflicts of interest. We have no conflicts of interest. We have no affiliation with any pharmaceutical companies, supplement companies, governments, political parties, or advocacy organizations.

Disclaimer. We do not provide medical advice. No treatment is 100% effective, and all may have side effects. Protocols combine multiple treatments. Consult a qualified physician for personalized risk/benefit analysis.

AI. We use AI models (Gemini, Grok, Claude, and ChatGPT) tasked with functioning as additional peer-reviewers to check for errors, suggest improvements, and review spelling and grammar. Any corrections are manually verified. Our preference for em dashes is independent of AI.

Updates. Our COVID-19 meta-analyses involve the extraction of over 227,000 datapoints from thousands of papers for 226 treatments. We thank the thousands of scientists, physicians, and other contributors that have provided updates, suggestions, feedback, and corrections. These are all welcome and can be submitted at <https://c19early.org/semeta.html>.


Dedication. This work is dedicated to top evidence-based physicians that worked tirelessly to analyze evidence and greatly reduce mortality and morbidity during the pandemic. In alphabetical order: Dr. Thomas J. Borody, Dr. Mary Talley Bowden, Dr. Flavio Cadegiani, Dr. Shankara Chetty, Dr. Ryan Cole, Dr. George Fareed, Dr. Sabine Hazan, Dr. Pierre Kory, Dr. Tess Lawrie, Dr. Robert Malone, Dr. Paul Marik, Dr. Peter McCullough, Dr. Didier Raoult, Dr. Harvey Risch, Dr. Jackie Stone, Dr. Brian Tyson, Dr. Joseph Varon, and Dr. Vladimir Zelenko.

Public domain. This is a public domain work distributed in accordance with the Creative Commons CC0 1.0 Universal license, which dedicates the work to the public domain by waiving all rights worldwide under copyright law. You can distribute, remix, adapt, and build upon this work in any medium or format, including for commercial purposes, without asking permission. Referenced material and third-party images retain any original copyrights or restrictions. See: <https://creativecommons.org/publicdomain/zero/1.0/>.

Study Notes

Du Laing

Selenium for COVID-19 Du Laing et al. SUFFICIENCY



Are selenium levels associated with COVID-19 outcomes?

Retrospective 73 patients in Belgium

Lower mortality with higher selenium levels ($p=0.0014$)

Du Laing et al., Nutrients, September 2021

c19early.org


Retrospective 73 hospitalized COVID-19 patients in Belgium, showing higher risk of mortality with selenium deficiency and zinc deficiency.

Ghoweba

Estimated 100 patient selenium late treatment RCT with results not reported over 4 years after estimated completion.

Hafizi

Selenium Hafizi et al. LATE TREATMENT RCT



Is **late** treatment with selenium + BCc1 beneficial for COVID-19?

Double-blind RCT 122 patients in Iran (October 2020 - March 2021)

Trial underpowered to detect differences

Hafizi et al., Trials, November 2023

c19early.org

Randomized, double-blind, placebo-controlled trial of 122 moderate hospitalized COVID-19 patients in Iran, evaluating the addition of BCc1 iron chelator and Hep-S selenium nanomedicines to standard treatment. The nanomedicine group showed a significant 77% reduction in IL-6 levels by day 28 compared to an 18% increase in the placebo group, along with improvements in TNF-alpha and clinical scores for cough, fatigue, and oxygen need, without statistical significance.

There are several issues with this trial:

Outcome switching versus registration - the registry describes a four-arm trial (BCc1 alone, Hep-S alone, combination, placebo) with hospitalization period, mortality, and lung CT as primary outcomes. The paper reports only two arms, drops the two single-agent arms, changes the dosing, and presents IL-6 - not a registered primary outcome - as the primary endpoint. The one significant result is for a new endpoint while the registered primary outcomes are null or un-analyzed.

Degrees of freedom imply impossible sample sizes - in repeated-measures ANOVA the error degrees of freedom are fixed by the number of subjects, yet they imply mutually incompatible Ns from the same cohort - ferritin implies ~7 patients, AST/WBC/HCT imply ~94-96, and even within the cytokines IL-6 implies 21 while TNF and IFN-γ imply 22. The same patients at the same visits cannot yield these. The ferritin analysis as printed is uninterpretable.

Group sizes contradict each other - allocation is stated as 62 treatment and 60 placebo, but Table 3's sex counts sum to 65 and 57, and the CONSORT analysis boxes (58 and 57) don't reconcile with the stated dropouts either. The study's own denominator is unstable across the abstract, figure, and tables.

Headline result is unverifiable - the 77% IL-6 reduction versus 18% increase cannot be checked against any reported figure - no IL-6 means appear anywhere in the paper or supplement. Table 4 gives only sums of squares, F, and p, never the group means the percentages derive from.

Misreported significance - the text labels the IL-6 main effect of time as "significant" when its p-value is 0.219; only the time x group interaction ($p=0.041$) is actually significant.


Contradictory recruitment dates - the methods give a backwards, impossible range (Oct 2 to Mar 20, 2020) while the results and registry report Oct 2020-Mar 2021.

No power calculation; very small, opaque primary analysis - there was no pre-specified sample size, and the primary cytokine outcome has only 11 patients per group, selected by an unstated mechanism.

Conflict of interest - the manufacturer (whose owner is the senior author) synthesized the compound, ran the experiments, analyzed the data, and wrote the manuscript.

Holt

Selenium for COVID-19 COVIDENCE UK PROPHYLAXIS



Does selenium reduce COVID-19 infections?

Prospective study of 15,227 patients in the United Kingdom (May 2020 - Feb 2021)

Fewer cases with selenium (not stat. sig., $p=0.11$)


Holt et al., Thorax, March 2021

c19early.org

Prospective survey-based study with 15,227 people in the UK, showing lower risk of COVID-19 cases with vitamin A, vitamin D, zinc, selenium, probiotics, and inhaled corticosteroids; and higher risk with metformin and vitamin C. Statistical significance was not reached for any of these. Except for vitamin D, the results for treatments we follow were only adjusted for age, sex, duration of participation, and test frequency.

Im

Selenium for COVID-19 Im et al. SUFFICIENCY



Are selenium levels associated with COVID-19 outcomes?

Retrospective 49 patients in South Korea

Lower ventilation with higher selenium levels ($p=0.028$)


Im et al., Int. J. Infectious Diseases, Aug 2020

c19early.org

Analysis of 50 hospitalized COVID-19 patients in South Korea showing 42% of patients with selenium deficiency, and lower mechanical ventilation with selenium sufficiency.

Majeed

Selenium for COVID-19 Majeed et al. SUFFICIENCY



Are selenium levels associated with COVID-19 outcomes?

Prospective study of 60 patients in India

Fewer cases with higher selenium levels (not stat. sig., $p=0.057$)


Majeed et al., Nutrition, February 2021

c19early.org

Analysis of 30 COVID-19 patients and 30 healthy controls in India, showing significantly lower selenium levels in COVID-19 patients. 43.3% of COVID-19 patients had selenium levels <70 ng/mL compared to 20% of controls.

Moghaddam

Selenium for COVID-19 Moghaddam et al. SUFFICIENCY



Are selenium levels associated with COVID-19 outcomes?

Retrospective 166 patients in Germany

Lower mortality with higher selenium levels ($p=0.011$)


Moghaddam et al., Nutrients, July 2020

c19early.org

Analysis of 33 COVID-19 patients showing selenium levels significantly lower than reference levels, and significantly lower levels in non-survivors compared with survivors.

Mohamed

Selenium for COVID-19 Mohamed et al. SUFFICIENCY



Are selenium levels associated with COVID-19 outcomes?

Retrospective 60 patients in Egypt (June 2023 - May 2024)

Lower mortality with higher selenium levels ($p=0.024$)


Mohamed et al., The Medical J. Cairo U., Dec 2024

c19early.org

Retrospective 60 hospitalized pediatric COVID-19 patients showing deficiencies in vitamin D, folic acid (B9), zinc, and selenium associated with higher mortality.

Nimer

Selenium for COVID-19 Nimer et al. PROPHYLAXIS



Is prophylaxis with selenium beneficial for COVID-19?

Retrospective 2,148 patients in Jordan (March - July 2021)

Higher hospitalization with selenium (not stat. sig., $p=0.48$)


Nimer et al., Bosnian J. Basic Medical..., Feb 2022

c19early.org

Retrospective 2,148 COVID-19 recovered patients in Jordan, showing no significant differences in the risk of severity and hospitalization with selenium prophylaxis.

Rozemeijer

Selenium for COVID-19 Rozemeijer et al. SUFFICIENCY



Are selenium levels associated with COVID-19 outcomes?

Prospective study of 25 patients in Netherlands

Lower ICU admission with higher selenium levels (not stat. sig., $p=0.093$)


Rozemeijer et al., *Nutrients*, January 2024

c19early.org

Prospective pilot study of 20 critically ill COVID-19 ICU patients showing high deficiency rates of 50-100% for vitamins A, B6, and D; zinc; and selenium at admission. Deficiencies of vitamins B6 and D, and low iron status, persisted after 3 weeks. Plasma levels of vitamins A and E, zinc, and selenium increased over time as inflammation resolved, suggesting redistribution may explain some observed deficiencies. All patients received daily micronutrient administration. Additional intravenous and oral micronutrient administration for 10 patients did not significantly impact micronutrient levels or deficiency rates, however authors note that the administered doses may be too low. The form of vitamin D is not specified but may have been cholecalciferol which is expected to have a very long onset of action compared to more appropriate forms such as calcifediol or calcitriol.

Vaisi

Selenium for COVID-19 Vaisi et al. PROPHYLAXIS



Is prophylaxis with selenium beneficial for COVID-19?

Retrospective 3,955 patients in Iran

Lower hospitalization ($p=0.018$) and fewer symptomatic cases ($p=0.042$)


Vaisi et al., *The Clinical Respiratory...*, May 2023

c19early.org

Analysis of nutrient intake and COVID-19 outcomes for 3,996 people in Iran, showing lower risk of COVID-19 hospitalization with sufficient vitamin A, vitamin C, and selenium intake, with statistical significance for vitamin A and selenium.

Voelkle

Selenium for COVID-19 Voelkle et al. SUFFICIENCY



Are selenium levels associated with COVID-19 outcomes?

Prospective study of 57 patients in Switzerland (Mar - Apr 2020)

Study underpowered to detect differences


Voelkle et al., *Nutrients*, April 2022

c19early.org

Prospective study of 57 consecutive hospitalized COVID-19 patients in Switzerland, showing higher risk of mortality/ICU admission with vitamin A, vitamin D, and zinc deficiency, with statistical significance only for vitamin A and zinc. Adjustments only considered age.

Wozniak

Selenium for COVID-19 Wozniak et al. ICU PATIENTS



Are selenium levels associated with COVID-19 outcomes?

Retrospective 118 patients in Switzerland (March - May 2020)

Lower mortality ($p=0.1$) and progression ($p=0.2$), not sig.

Wozniak et al., *Nutrients*, July 2023

c19early.org

Retrospective 345 COVID-19 patients in Switzerland, showing significantly different selenium levels with ICU patients < hospitalized patients < outpatients.

For ICU patients, there was higher mortality, septic shock, and mechanical ventilation days with lower selenium levels, with statistical significance only for ventilation.

Appendix 1. Methods and Data

Search methods

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org, which regularly receives notification of studies upon publication. Search terms are selenium and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of selenium for COVID-19 that report a comparison with a control group are included in the main analysis. Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. Studies with major unexplained data issues, for example major outcome data that is impossible to be correct with no response from the authors, are excluded.

Effect extraction

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome-specific analyses. For example, if effects for mortality and cases are reported then they are both used in specific outcome analyses, while mortality is used for pooled analysis. If symptomatic results are reported at multiple times, we use the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes.




Fig. 24. Mid-recovery results can more accurately reflect efficacy when almost all patients recover. Mateja et al. confirm that intermediate viral load results more accurately reflect hospitalization/death.

Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral outcomes. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. An IPD meta-analysis confirms that intermediate viral load reduction is more closely associated with hospitalization/death than later viral load reduction¹³⁷. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO₂ is more important than cough.

Statistical methods

Forest plots are computed using PythonMeta¹³⁸ with the DerSimonian and Laird random-effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the I² statistic. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to Zhang (B) *et al.* Reported confidence intervals and *p*-values are used when available, and adjusted values are used when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported *p*-values and confidence intervals followed Altman, Altman (B), and Fisher's exact test was used to calculate *p*-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1¹⁴². Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.14.7) with scipy (1.18.1), pythonmeta (1.26), numpy (2.5.2), statsmodels (0.15.0), and plotly (6.9.0). Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor (4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a *p*-value less than 0.05 was considered statistically significant. Grobid 0.8.2 is used to parse PDF documents.

When evaluating potential effect modification across groups, we use an interaction test as described by Altman (C) *et al.* We compared the log-transformed relative risks using a *z*-test, deriving the standard error of the difference from the 95% confidence intervals. A two-sided interaction *p*-value of < 0.05 was considered a statistically significant difference in treatment effect between the groups.

Quality evaluation

Cochrane RoB 2/ROBINS-I are often used to evaluate studies, and have the advantage of providing standardized rules that can be applied with minimal understanding of the domain and study. However, the rules do not account for many real-world issues, often overemphasize or underemphasize others, and studies show low inter-rater reliability¹⁵⁰. Certain domains are more applicable for these tools, however the time-sensitive nature of a pandemic, with significant mortality for every day of delay in evidence assessment, and the characteristics of COVID-19 make them inappropriate for this domain. This can be demonstrated with examples where expert RoB 2/ROBINS-I ratings do not match reality for COVID-19. Popp *et al.* use RoB 2 to classify Reis *et al.* as low risk of bias, however this is the opposite of reality—the trial not only has very high risk of bias, but has very high actual known bias, refusing to release data despite pledging to, reporting multiple impossible numbers, having blinding

and randomization failure, and many other issues¹⁵². Axfors *et al.* use RoB 2 to classify Horby *et al.* as low risk of bias, however this is the opposite of reality—the very late treatment and excessive dosage used produces results with no relevance to recommended usage. HCQ shows poor results with late treatment and excessive dosage, and the combination shows harm^B. Hempenius *et al.* use ROBINS-I to classify 33 studies for HCQ. The two rated as having the lowest risk of bias^{148,149} are far from the most informative. Both involve very late treatment, providing no information on recommended usage, and ROBINS-I does a very poor job of accounting for the impact of confounding factors^C.

Our quality evaluation focuses on known issues and bias, and the potential impact on outcomes, rather than just the risk of bias. The estimated potential impact of each confounding factor, and the direction of the impact is considered. For example, consider a study that shows significantly lower risk, the value of the study varies significantly if confounding points to an underestimate or an overestimate of efficacy. In one case, the real effect may be null, while the other case provides stronger evidence of efficacy (which may be greater than the study shows). Analysis focusing on the risk of bias, while simpler, may penalize studies for theoretical or technical issues that have no or minimal impact on outcomes. Analysis also depends on the outcome, for example certain issues are less relevant for objective outcomes such as mortality. Inaccurate penalization, and inaccurate high-quality evaluation in the face of known major issues affecting outcomes, increases in significance during a pandemic when immediate recognition of new evidence is critical, and when considering all global studies, as required during a pandemic. Investigators in other countries may have different customs for design, analysis, and reporting, and different English language skills, however they may not be less diligent or have greater bias. Investigators in lower-pharmaceutical-profit countries may have lower bias towards profitable interventions.

Treatment time

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective^{70,71}.

Living analysis

This is a living analysis and is updated regularly. We received no funding, this research is done in our spare time. We have no affiliation with any pharmaceutical companies, supplement companies, governments, political parties, or advocacy organizations.

A summary of study results is below. Please submit updates and corrections at <https://c19early.org/semeta.html>.

Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

.

Late treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

<i>Howe</i> , 12/15/2021, Double Blind Randomized Controlled Trial, USA, trial NCT04869579 (history) (SeCOVID).	Estimated 100 patient RCT with results unknown and over 4 years late.
<i>Hafizi</i> , 11/11/2023, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 17 authors, study period 2 October, 2020 - 20 March, 2021, this trial uses multiple treatments in the treatment arm (combined with BCC1) - results of individual treatments may vary, trial IRCT20170731035423N2, excluded in exclusion analyses: data issues pending author response.	risk of death, 35.5% lower, RR 0.65, $p = 0.68$, treatment 2 of 62 (3.2%), control 3 of 60 (5.0%), NNT 56.

Prophylaxis

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

<i>Holt</i> , 3/30/2021, prospective, United Kingdom, peer-reviewed, 34 authors, study period 1 May, 2020 - 5 February, 2021, trial NCT04330599 (history) (COVIDENCE UK), excluded in exclusion analyses: significant unadjusted confounding possible.	risk of case, 79.5% lower, RR 0.20, $p = 0.11$, treatment 1 of 167 (0.6%), control 445 of 15,060 (3.0%), NNT 42, adjusted per study, odds ratio converted to relative risk, minimally adjusted, group sizes approximated.
<i>Nimer</i> , 2/28/2022, retrospective, Jordan, peer-reviewed, survey, 4 authors, study period March 2021 - July 2021.	risk of hospitalization, 26.3% higher, RR 1.26, $p = 0.48$, treatment 12 of 57 (21.1%), control 207 of 2,091 (9.9%), adjusted per study, odds ratio converted to relative risk, multivariable. risk of severe case, 8.7% higher, RR 1.09, $p = 0.80$, treatment 12 of 57 (21.1%), control 248 of 2,091 (11.9%), adjusted per study, odds ratio converted to relative risk, multivariable.
<i>Vaisi</i> , 5/11/2023, retrospective, Iran, peer-reviewed, 5 authors.	risk of hospitalization, 53.1% lower, HR 0.47, $p = 0.02$, treatment 3,853, control 102, adjusted per study, inverted to make HR<1 favor treatment, sufficient vs. insufficient intake, multivariable, Cox proportional hazards. risk of symptomatic case, 15.3% lower, HR 0.85, $p = 0.04$, treatment 3,853, control 102, adjusted per study, inverted to make HR<1 favor treatment, sufficient vs. insufficient intake, multivariable, Cox proportional hazards.

Evaluation Notes

Analyzing the data from first principles is always important, and may be especially important for COVID-19. Bias in the design, analysis, and reporting of clinical studies has long been reported, and may be increased for COVID-19 due to politicization. For example, Scott Alexander noted that *"if you say anything in favor of ivermectin you will be cast out of civilization and thrown into the circle of social hell reserved for Klan members and 1/6 insurrectionists. All the health officials in the world will shout 'horse dewormer!' at you and compare you to Josef Mengele."*⁶⁷ Social pressure to report politically acceptable results was very strong. There may therefore be unusually strong bias in design, analysis, and reporting. For example, Prof. Greenland reports that *Hayward et al.* applied an unjustified and undisclosed extremely tight, null-centered Bayesian prior that biases towards more politically acceptable results¹⁵⁷. While the politicization focused on certain treatments, it was not limited to them. For example, media coverage was highly biased against positive results for low-cost treatments¹⁵⁸ across the 226 treatments we cover. Studies should be evaluated from first principles, incorporating the treatment delay, treatment regimen, patient population, and other confounding factors. For COVID-19, there is no significant difference in the results of RCTs compared to observational studies, RR 0.97 [0.91-1.03]⁶¹—in both cases bias varies from minimal to extreme, and all studies must be evaluated individually.

US authorities claim only three high-profit drugs from companies with strong US lobbying are beneficial for early treatment (2 repurposed drugs - remdesivir and molnupiravir, and one novel drug - nirmatrelvir)^D. COVID-19 involves the interplay of many viral and host proteins and factors, providing over 500 therapeutic targets¹⁵⁹. Given the 12,000+ proposed treatments⁴⁶, existing results for many treatments with overlapping secondary complications and therapeutic targets, and the combination of known safety and pharmacokinetics for certain treatments along with strong mechanistic evidence, the probability of only 3 high-profit drugs from top lobbying companies being beneficial is extremely low. This likely reflects a bias toward evaluation of drugs with strong financial resources and efforts devoted to passing the US approval process, and very limited or non-existing evaluation of low-cost treatments. Indeed, official recommendations varied widely between countries¹⁶⁰. Some countries evaluated limited low-cost treatments early and 25 low-cost treatments were approved in one or more countries¹⁶⁰.

Contrary to claims found online, we analyze both all studies and higher-quality studies (with evaluation focusing on known issues and bias, and the potential impact on outcomes, rather than just the risk of bias), we analyze specific outcomes and pooled outcomes (with extensive analysis and validation of pooled outcomes), and we do not include preclinical studies or retracted studies in meta-analysis. Pooled outcomes can detect efficacy earlier but do not bias towards efficacy—the inclusion of less appropriate designs such as very late treatment may hide efficacy for appropriate use.

Supplementary Data

Supplementary Data

Footnotes

- Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.

- b. When administered late in infection, HCQ may enhance viral egress by further increasing lysosomal pH beyond the effect of ORF3a's water channel activity, thereby promoting lysosomal exocytosis, inactivating degradative enzymes, and facilitating the release of SARS-CoV-2 particles into the extracellular environment^{144,145}. Research also suggests potential cardioprotective effects at lower doses, but cardiotoxicity with excessive dosage¹⁴⁶. *Bobrowski et al.* also indicate negative effects if HCQ and remdesivir are combined.
- c. *Peters et al.* is subject to confounding by calendar-time (SOC evolved rapidly early in the pandemic, the linear covariate does not reflect non-linear SOC changes and hospital specific effects), hospital type (non-treatment hospitals were tertiary university centers), confounding by indication (4/7 hospitals initiated treatment on deterioration), immortal-time bias for as-treated (exposure assigned after baseline), significant differences for other experimental treatments, potential overadjustment from collider bias (steroid use and indication bias), limited baseline severity information, differences in hospice referral propensity across hospitals, unadjusted difference in time from onset to admission, difference in PCR positivity, and other factors. *Mahévas et al.* is subject to confounding by hospital (treatment highly dependent on the hospital, different SOC/ICU transfer practices, not included in PS), immortal time (only partly addressed in sensitivity analysis), co-treatment differences, calendar-time (SOC evolved rapidly early in the pandemic), binary coding for age (age ≥65 despite steep age-risk gradient), residual imbalance (variables dropped from PS), a composite outcome dependent on hospital triage/capacity, and other factors.
- d. Monoclonal antibodies were previously included. Other treatments such as dexamethasone, tocilizumab, and baricitinib were recommended for late stage hospitalized patients.

References

1. *Ghoweba et al.*, Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients, NCT04869579, clinicaltrials.gov/study/NCT04869579.
2. *Galmés et al.*, Suboptimal Consumption of Relevant Immune System Micronutrients Is Associated with a Worse Impact of COVID-19 in Spanish Populations, *Nutrients*, doi:10.3390/nu14112254.
3. *Galmés (B) et al.*, Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework, *Nutrients*, doi:10.3390/nu12092738.
4. *Crawford et al.*, Analysis of Select Dietary Supplement Products Marketed to Support or Boost the Immune System, *JAMA Network Open*, doi:10.1001/jamanetworkopen.2022.26040.
5. *Crighon et al.*, Toxicological screening and DNA sequencing detects contamination and adulteration in regulated herbal medicines and supplements for diet, weight loss and cardiovascular health, *Journal of Pharmaceutical and Biomedical Analysis*, doi:10.1016/j.jpba.2019.112834.
6. *Chanyandura et al.*, Evaluation of The Pharmaceutical Quality of the Most Commonly Purchased Vitamin C (Ascorbic Acid) Formulations in COVID-19 Infection in South Africa, *J. Basic Appl. Pharm. Sci.*, doi:10.33790/jbaps1100105.
7. *Fan et al.*, Zinc and selenium status in coronavirus disease 2019, *BioMetals*, doi:10.1007/s10534-023-00501-0.
8. *Ryu et al.*, Fibrin drives thromboinflammation and neuropathology in COVID-19, *Nature*, doi:10.1038/s41586-024-07873-4.
9. *Rong et al.*, Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19, *Cell Host & Microbe*, doi:10.1016/j.chom.2024.11.007.
10. *Yang et al.*, SARS-CoV-2 infection causes dopaminergic neuron senescence, *Cell Stem Cell*, doi:10.1016/j.stem.2023.12.012.
11. *Scardua-Silva et al.*, Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19, *Scientific Reports*, doi:10.1038/s41598-024-52005-7.
12. *Hampshire et al.*, Cognition and Memory after Covid-19 in a Large Community Sample, *New England Journal of Medicine*, doi:10.1056/NEJMoa2311330.
13. *Duloquin et al.*, Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2, *Journal of Clinical Medicine*, doi:10.3390/jcm13051397.
14. *Sodagar et al.*, Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches, *Biomolecules*, doi:10.3390/biom12070971.
15. *Sagar et al.*, COVID-19-associated cerebral microbleeds in the general population, *Brain Communications*, doi:10.1093/braincomms/fcae127.
16. *Verma et al.*, Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations, *bioRxiv*, doi:10.1101/2024.06.02.596989.
17. *Panagea et al.*, Neurocognitive Impairment in Long COVID: A Systematic Review, *Archives of Clinical Neuropsychology*, doi:10.1093/arclin/acae042.
18. *Ariza et al.*, COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations, *Biomedicines*, doi:10.3390/biomedicines12061147.
19. *Vashisht et al.*, Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications, *Viruses*, doi:10.3390/v16081183.
20. *Ahmad et al.*, Neurological Complications and Outcomes in Critically Ill Patients With COVID-19: Results From International Neurological Study Group From the COVID-19 Critical Care Consortium, *The Neurohospitalist*, doi:10.1177/19418744241292487.
21. *Wang et al.*, SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction, *Translational Neurodegeneration*, doi:10.1186/s40035-024-00458-1.
22. *Freitas et al.*, Central nervous system and systemic inflammatory networks associated with acute neurological outcomes in COVID-19, *Scientific Reports*, doi:10.1038/s41598-025-08632-9.
23. *Lu et al.*, Risk of neuropsychiatric and related conditions associated with SARS-CoV-2 infection: a difference-in-differences analysis, *Nature Communications*, doi:10.1038/s41467-025-61961-1.
24. *Jachman-Kapufka et al.*, Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants—Single-Center Study, *Brain Sciences*, doi:10.3390/brainsci14111161.
25. *Beckman et al.*, SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19, *Cell Reports*, doi:10.1016/j.celrep.2022.111573.
26. *Eberhardt et al.*, SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels, *Nature Cardiovascular Research*, doi:10.1038/s44161-023-00336-5.
27. *Van Tin et al.*, Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling, *Cells*, doi:10.3390/cells13161331.
28. *Borka Balas et al.*, COVID-19 and Cardiac Implications—Still a Mystery in Clinical Practice, *Reviews in Cardiovascular Medicine*, doi:10.31083/j.rcm2405125.
29. *Altaweel et al.*, An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID-19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies, *Archives of Microbiology & Immunology*, doi:10.26502/ami.936500177.
30. *Saha et al.*, COVID-19 beyond the lungs: Unraveling its vascular impact and cardiovascular complications—mechanisms and therapeutic implications, *Science Progress*, doi:10.1177/00368504251322069.
31. *Yin et al.*, COVID-19: a vascular nightmare unfolding, *Frontiers in Immunology*, doi:10.3389/fimmu.2025.1593885.
32. *Bruno et al.*, Accelerated vascular ageing after COVID-19 infection: the CARTE-SIAN study, *European Heart Journal*, doi:10.1093/eurheartj/ehaf430.

33. **Abiri et al.**, The silent legacy of COVID-19: exploring genomic instability in long-term COVID-19 survivors, BMC Infectious Diseases, doi:10.1186/s12879-025-11419-y.
34. **Gioia et al.**, SARS-CoV-2 infection induces DNA damage, through CHK1 degradation and impaired 53BP1 recruitment, and cellular senescence, Nature Cell Biology, doi:10.1038/s41556-023-01096-x.
35. **Doğan et al.**, Clinical Investigation of Leukocyte DNA Damage in COVID-19 Patients, Current Issues in Molecular Biology, doi:10.3390/cimb45020062.
36. **Rueda-Torres et al.**, Longitudinal Assessment of DNA Damage in PBMCs From Hospitalized COVID-19 Patients via Alkaline Comet Assay, Environmental and Molecular Mutagenesis, doi:10.1002/em.70055.
37. **Trender et al.**, Changes in memory and cognition during the SARS-CoV-2 human challenge study, eClinicalMedicine, doi:10.1016/j.eclim.2024.102842.
38. **Dugied et al.**, Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization, Communications Biology, doi:10.1038/s42003-025-07933-z.
39. **Malone et al.**, Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.
40. **Murigneux et al.**, Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly, Nature Communications, doi:10.1038/s41467-024-44958-0.
41. **Lv et al.**, Host proviral and antiviral factors for SARS-CoV-2, Virus Genes, doi:10.1007/s11262-021-01869-2.
42. **Lui et al.**, Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling, Virology, doi:10.1128/mbio.00392-24.
43. **Niarakis et al.**, Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches, Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859.
44. **Katiyar et al.**, SARS-CoV-2 Assembly: Gaining Infectivity and Beyond, Viruses, doi:10.3390/v16111648.
45. **Wu et al.**, Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition, RNA Biology, doi:10.1080/15476286.2024.2433830.
46. **c19early.org**, c19early.org/treatments.html.
47. **EFSA**, Scientific Opinion on the substantiation of health claims related to selenium and protection of DNA, proteins and lipids from oxidative damage (ID 277, 283, 286, 1289, 1290, 1291, 1293, 1751), function of the immune system (ID 278), thyroid function (ID 279, 282, 286, 1289, 1290, 1291, 1293), function of the heart and blood vessels (ID 280), prostate function (ID 284), cognitive function (ID 285) and spermatogenesis (ID 396) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, EFSA Journal, doi:10.2903/j.efsa.2009.1220.
48. **Yuan et al.**, The role of cell death in SARS-CoV-2 infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01580-8.
49. **Xie et al.**, The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death, Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6.
50. **Sinha et al.**, Selective Impact of Selenium Compounds on Two Cytokine Storm Players, Preprints, doi:10.20944/preprints202308.1168.v1.
51. **Hajdrik et al.**, In Vitro Determination of Inhibitory Effects of Humic Substances Complexing Zn and Se on SARS-CoV-2 Virus Replication, Foods, doi:10.3390/foods11050694.
52. **Zhou et al.**, Metal-coding assisted serological multi-omics profiling deciphers the role of selenium in COVID-19 immunity, Chemical Science, doi:10.1039/d3sc03345g.
53. **Jadad et al.**, Randomized Controlled Trials: Questions, Answers, and Musings, Second Edition, doi:10.1002/9780470691922.
54. **Göttsche, P.**, Bias in double-blind trials, Doctoral Thesis, University of Copenhagen, www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trials-doctoral-thesis/.
55. **Als-Nielsen et al.**, Association of Funding and Conclusions in Randomized Drug Trials, JAMA, doi:10.1001/jama.290.7.921.
56. **Bekelman et al.**, Scope and Impact of Financial Conflicts of Interest in Biomedical Research, JAMA, doi:10.1001/jama.289.4.454.
57. **Lundh et al.**, Industry sponsorship and research outcome, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.MR000033.pub3.
58. **c19early.org (B)**, c19early.org/sesupp.html#fig_rctobs.
59. **Concato et al.**, Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs, New England Journal of Medicine, doi:10.1056/NEJM200006223422507.
60. **Anglemeyer et al.**, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.MR000034.pub2.
61. **c19early.org (C)**, c19early.org/rctobs.html.
62. **Lee et al.**, Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines, Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482.
63. **Deaton et al.**, Understanding and misunderstanding randomized controlled trials, Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005.
64. **Nichol et al.**, Challenging issues in randomised controlled trials, Injury, 2010, doi:10.1016/j.injury.2010.03.033, www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.
65. **Hafizi et al.**, Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial, Trials, doi:10.1186/s13063-023-07624-2.
66. **Holt et al.**, Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK), Thorax, doi:10.1136/thoraxjnl-2021-217487.
67. **web.archive.org**, web.archive.org/web/20211117052139/https://astralcodexten.substack.com/p/ivermectin-much-more-than-y...
68. **altmetric.com**, www.altmetric.com/.
69. **help.altmetric.com**, help.altmetric.com/support/solutions/articles/6000235983-attention-sources-tracked-by-altmetric.
70. **Treanor et al.**, Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.
71. **McLean et al.**, Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.
72. **Ikematsu et al.**, Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts, New England Journal of Medicine, doi:10.1056/NEJMoa1915341.
73. **Hayden et al.**, Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents, New England Journal of Medicine, doi:10.1056/NEJMoa1716197.
74. **Kumar et al.**, Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00469-2.
75. **López-Medina et al.**, Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2021.3071.
76. **Korves et al.**, SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk, medRxiv, doi:10.1101/2024.03.08.24303818.
77. **Faria et al.**, Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil, Science, doi:10.1126/science.abh2644.

78. **Nonaka** et al., SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021, *International Journal of Infectious Diseases*, doi:10.1016/j.ijid.2021.08.003.
79. **Karita** et al., Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection, medRxiv, doi:10.1101/2021.08.27.21262754.
80. **Zavascki** et al., Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil, *Research Square*, doi:10.21203/rs.3.rs-910467/v1.
81. **Willett** et al., The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism, medRxiv, doi:10.1101/2022.01.03.21268111.
82. **Peacock** et al., The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry, *bioRxiv*, doi:10.1101/2021.12.31.474653.
83. **Williams**, T., Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources, Do Your Own Research, *doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal*.
84. **Xu** et al., A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR, *Rapid Communications in Mass Spectrometry*, doi:10.1002/rcm.9358.
85. **Jitobaom** et al., Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2, *Research Square*, doi:10.21203/rs.3.rs-941811/v1.
86. **Jitobaom (B)** et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, *BMC Pharmacology and Toxicology*, doi:10.1186/s40360-022-00580-8.
87. **Jeffreys** et al., Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2, *International Journal of Antimicrobial Agents*, doi:10.1016/j.ijantimicag.2022.106542.
88. **Ostrov** et al., Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells, *Pathogens*, doi:10.3390/pathogens10111514.
89. **Alsaidi** et al., Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model, *Marine Drugs*, doi:10.3390/md19080418.
90. **Andreani** et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, *Microbial Pathogenesis*, doi:10.1016/j.micpath.2020.104228.
91. **De Forni** et al., Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients, *PLoS ONE*, doi:10.1371/journal.pone.0276751.
92. **Wan** et al., Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level, *Scientific Reports*, doi:10.1038/s41598-024-54722-5.
93. **Said** et al., The effect of *Nigella sativa* and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial, *Frontiers in Pharmacology*, doi:10.3389/fphar.2022.1011522.
94. **Fiaschi** et al., In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants, *Viruses*, doi:10.3390/v16020168.
95. **Xing** et al., Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals, *Briefings in Bioinformatics*, doi:10.1093/bib/bbab249.
96. **Chen** et al., Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir, *ACS Pharmacology & Translational Science*, doi:10.1021/acspsci.1c00022.
97. **Hempel** et al., Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties, *Chemical Science*, doi:10.1039/D1SC01494C.
98. **Schultz** et al., Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2, *Nature*, doi:10.1038/s41586-022-04482-x.
99. **Ohashi** et al., Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment, *iScience*, doi:10.1016/j.isci.2021.102367.
100. **Al Krad** et al., The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication, *bioRxiv*, doi:10.1101/2025.03.09.642200.
101. **Abd Elsalam** et al., Anti-COVID-19 activity and simple HPLC method for concurrent detection of repurposed drugs in novel binary mixtures, *AMB Express*, doi:10.1186/s13568-026-02030-8.
102. **Rana** et al., Ivermectin and Doxycycline combination as a promising anti-viral drug candidate: an in-silico and DFT study, *In Silico Pharmacology*, doi:10.1007/s40203-026-00576-w.
103. **Setz** et al., Synergistic Virus Neutralizing Activities of European Black Elderberry Fruit Extract and Iota-Carrageenan Against SARS-CoV-2, Influenza A Virus and Respiratory Syncytial Virus, *Nutrients*, doi:10.3390/nu18081205.
104. **Ali** et al., Preclinical Screening Platform Identifies Azatadine-Dimaleate as a Potent Repurposed Therapeutic Against SARS-CoV-2 Infection, *Journal of Medical Virology*, doi:10.1002/jmv.70713.
105. **Lew** et al., Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections, *Cells*, doi:10.3390/cells15131146.
106. **Khatun** et al., An All-Oral Antiviral Combination Strategy against COVID-19 Enabled by the Synergistic Mechanism of Action of Auranofin and Remdesivir, *Elsevier BV*, doi:10.2139/ssrn.6942990.
107. **How** et al., The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages, *International Journal of Molecular Sciences*, doi:10.3390/ijms27167316.
108. **Tan** et al., Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection, *Frontiers in Cellular and Infection Microbiology*, doi:10.3389/fcimb.2021.700502.
109. **Thairu** et al., A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality, *Journal of Pharmaceutical Research International*, doi:10.9734/jpri/2022/v34i44A36328.
110. **Singh** et al., The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis, *Journal of Antimicrobial Chemotherapy*, doi:10.1093/jac/dkac045.
111. **Meneguesso**, A., Médica defende tratamento precoce da Covid-19, *www.youtube.com/watch?v=X5FCrIm_19U*.
112. **Boulware**, D., Comments regarding paper rejection, *twitter.com/boulware_dr/status/1311331372884205570*.
113. **Meeus**, G., Online Comment, *twitter.com/gertmeeus_MD/status/1386636373889781761*.
114. **twitter.com**, *twitter.com/KashPrime/status/1768487878454124914*.
115. **Smail** et al., Antioxidant and oxidative enzymes, genetic variants, and cofactors as prognostic biomarkers of COVID-19 severity and mortality: a systematic review, *Frontiers in Molecular Biosciences*, doi:10.3389/fmolb.2025.1700263.
116. **Sarker** et al., Selenium as a Nutritional Shield in Viral Defense: A Narrative Review, *MDPI AG*, doi:10.20944/preprints202502.2251.v1.
117. **Sanduzzi Zamparelli** et al., Immune-Boosting and Antiviral Effects of Antioxidants in COVID-19 Pneumonia: A Therapeutic Perspective, *Life*, doi:10.3390/life15010113.

118. **Fazli** et al., Possible Link between Gut Microbiota, Diet, and COVID-19 Infection, *Journal of Medical Bacteriology*, 12:4, jmb.tums.ac.ir/index.php/jmb/article/view/525.
119. **Kaushal**, A., Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections, *Journal of Translational Medicine*, doi:10.1186/s12967-024-05587-9.
120. **Mu** et al., Anti-inflammatory and Nutritional Interventions Against SARS-CoV-2: A Comprehensive Review, *Journal of Agriculture and Food Research*, doi:10.1016/j.jafr.2024.101422.
121. **Maia** et al., Selenium—More than Just a Fortuitous Sulfur Substitute in Redox Biology, *Molecules*, doi:10.3390/molecules29010120.
122. **Golin** et al., Relationship between selenium status, selenoproteins and COVID-19 and other inflammatory diseases: A critical review, *Journal of Trace Elements in Medicine and Biology*, doi:10.1016/j.jtemb.2022.127099.
123. **Foshati** et al., Antioxidants and clinical outcomes of patients with coronavirus disease 2019: A systematic review of observational and interventional studies, *Food Science & Nutrition*, doi:10.1002/fsn3.3034.
124. **Khatiwa** et al., A Mechanistic Link Between Selenium and Coronavirus Disease 2019 (COVID-19), *Current Nutrition Reports*, doi:10.1007/s13668-021-00354-4.
125. **Zhang** et al., Selenium and selenoproteins in viral infection with potential relevance to COVID-19, *Redox Biology*, doi:10.1016/j.redox.2020.101715.
126. **Alexander** et al., Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19, *Nutrients*, doi:10.3390/nu12082358.
127. **Vaisi** et al., The association between nutrients and occurrence of COVID-19 outcomes in the population of Western Iran: A cohort study, *The Clinical Respiratory Journal*, doi:10.1111/crj.13632.
128. **Nimer** et al., The impact of vitamin and mineral supplements usage prior to COVID-19 infection on disease severity and hospitalization, *Bosnian Journal of Basic Medical Sciences*, doi:10.17305/bjbm.2021.7009.
129. **Kieliszek** et al., Selenium supplementation in the prevention of coronavirus infections (COVID-19), *Medical Hypotheses*, doi:10.1016/j.mehy.2020.109878.
130. **Pedrosa** et al., Nutritional risk of vitamin D, vitamin C, zinc, and selenium deficiency on risk and clinical outcomes of COVID-19: A narrative review, *Clinical Nutrition ESPEN*, doi:10.1016/j.clnesp.2021.11.003.
131. **Guillin** et al., Selenium, Selenoproteins and Viral Infection, *Nutrients*, doi:10.3390/nu11092101.
132. **Yehia** et al., SARS-CoV-2 Spike Protein Induces Time-Dependent and Brain-Region-Specific Alterations in Ferroptosis Markers: A Preliminary Study in K18-hACE2 Mice, *International Journal of Molecular Sciences*, doi:10.3390/ijms27031526.
133. **Kianfar** et al., Nanomaterials and Vitamins to Combat Future Pandemics: Lessons from COVID-19: A Review, *Trends in Sciences*, doi:10.48048/tis.2026.11481.
134. **Zeng** et al., Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future, *Frontiers in Microbiology*, doi:10.3389/fmicb.2023.1232453.
135. **O. Abdellatif** et al., Fighting the Progress of COVID-19 by Enhancing Immunity: A Review of Traditional Sudanese Natural Products Containing Immune-Boosting Elements, *Journal for Research in Applied Sciences and Biotechnology*, doi:10.55544/jrasb.2.2.33.
136. **c19early.org (D)**, c19early.org/timeline.html.
137. **Mateja** et al., The choice of viral load endpoint in early phase trials of COVID-19 treatments aiming to reduce 28-day hospitalization and/or death, *The Journal of Infectious Diseases*, doi:10.1093/infdis/jiaf282.
138. **Deng**, H., PyMeta, Python module for meta-analysis, www.pymeta.com/.
139. **Zhang (B)** et al., What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes, *JAMA*, 80:19, 1690, doi:10.1001/jama.280.19.1690.
140. **Altman**, D., How to obtain the P value from a confidence interval, *BMJ*, doi:10.1136/bmj.d2304.
141. **Altman (B)** et al., How to obtain the confidence interval from a P value, *BMJ*, doi:10.1136/bmj.d2090.
142. **Sweeting** et al., What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, *Statistics in Medicine*, doi:10.1002/sim.1761.
143. **Altman (C)** et al., Interaction revisited: the difference between two estimates, *BMJ*, doi:10.1136/bmj.326.7382.219.
144. **Michelucci** et al., SARS-CoV-2 ORF3a accessory protein is a water-permeable channel that induces lysosome swelling, *Communications Biology*, doi:10.1038/s42003-024-07442-5.
145. **Ghosh** et al., β -Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway, *Cell*, doi:10.1016/j.cell.2020.10.039.
146. **Kamga Kapchoup** et al., In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives, *Frontiers in Pharmacology*, doi:10.3389/fphar.2023.1128382.
147. **Bobrowski** et al., Synergistic and Antagonistic Drug Combinations against SARS-CoV-2, *Molecular Therapy*, doi:10.1016/j.ymthe.2020.12.016.
148. **Peters** et al., Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine, *Clinical Microbiology and Infection*, doi:10.1016/j.cmi.2020.10.004.
149. **Mahévas** et al., Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, *BMJ* 2020, doi:10.1136/bmj.m1844.
150. **Minuzzi** et al., The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application, *Journal of Clinical Epidemiology*, doi:10.1016/j.jclinepi.2020.06.015.
151. **Popp** et al., Ivermectin for preventing and treating COVID-19, *Cochrane Database of Systematic Reviews*, doi:10.1002/14651858.CD015017.pub3.
152. **Reis** et al., Effect of Early Treatment with Ivermectin among Patients with Covid-19, *New England Journal of Medicine*, doi:10.1056/NEJMoa2115869.
153. **Axfors** et al., Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials, *Nature*, doi:10.1038/s41467-021-22446-z.
154. **Horby** et al., Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial, *NEJM*, doi:10.1056/NEJMoa2022926.
155. **Hempenius** et al., Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID-19, *Pharmacoepidemiology and Drug Safety*, doi:10.1002/pds.5632.
156. **Hayward** et al., Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes, *Journal of Infection*, doi:10.1016/j.jinf.2024.106130.
157. **ibc2024.org**, www.ibc2024.org/viewdocument/sander-greenland-ibc-2024-president.
158. **c19early.org (E)**, c19early.org/semeta.html#media.
159. **c19early.org (F)**, c19early.org/mechanisms.html.
160. **c19early.org (G)**, c19early.org/adoption.html.